Kassandra Fox, NP
Family · Louisville, KYNPI 1124795505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Coherus Oncology, Inc. at 28.3% of the total. Reporting peaked in 2022 at $201 and has fallen 87.3% since, to $26 in 2025. That places this record below the midpoint for family clinicians in KY, where the typical reported total is $464.
Across 8 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coherus Oncology, Inc.$68
- ADC Therapeutics America, Inc.$55
- Blueprint Medicines Corporation$30
- AstraZeneca$26
- Seagen Inc.$19
- Eisai Inc.$15
- plus $28 from 2 others
What the payments were for
- Food & beverage$240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coherus Oncology, Inc. | 1 | $68 |
| ADC Therapeutics America, Inc. | 1 | $55 |
| Blueprint Medicines Corporation | 1 | $30 |
| AstraZeneca | 1 | $26 |
| Seagen Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
How this compares
$240 in reported general payments places this provider in the 35th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $82,308 |
| Abiraterone Acetate | 21 | $58,573 |
| XareltoRivaroxaban | 24 | $14,157 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $1,378 |
| Ondansetron Hcl | 54 | $1,311 |
| Potassium Chloride | 31 | $1,092 |
| Warfarin Sodium | 110 | $822 |
| Mirtazapine | 29 | $674 |
| Olanzapine | 28 | $587 |
| Anastrozole | 30 | $480 |
| Levothyroxine Sodium | 60 | $436 |
| Triamcinolone Acetonide | 27 | $413 |
| LoperamideLoperamide Hcl | 11 | $369 |
| Duloxetine Hcl | 30 | $340 |
| Dexamethasone | 25 | $323 |
Paid to pharmacies, not to this prescriber.
Other family in Louisville
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Shelley WaldmanLouisville$59K
- Esther MuhsLouisville$44K
- Barbra CaveLouisville$41K
- Kayla WilsonLouisville$40K
- Christin ThompsonLouisville$38K
- Wendi HallerLouisville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.